Company intelligence / Profile preview

Ukko Solutions

Palo Alto, California, United Statesukkosolutions.com ↗

Ownership: Private
Employees: ~40
Development stage: Other

Overview

Ukko uses a proprietary AI-powered protein engineering platform to design safer versions of allergenic food proteins. Its lead program focuses on a novel therapy for peanut allergy that aims to re-train the immune system without triggering allergic reactions. The company also develops improved gluten proteins suitable for people with celiac disease and gluten sensitivities. Clinical-stage progress has been announced but no published results from human trials are available yet.

Therapeutic areas: GastroenterologyImmunology
Modalities: ProteinBiologicSmall molecule
Industry: Biotech

Partnerships

Leaps by Bayer (lead investor)TIME Ventures (Marc Benioff)OurCrowd

Beyond the preview

Go deeper on Ukko Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ukko Solutions.

Explore the full profile